Type your tag names separated by a space and hit enter

Remission rates with antithyroid drug therapy: continuing influence of iodine intake?

Abstract

We retrospectively reviewed the therapeutic efficacy of antithyroid drugs for Graves disease. Sixty-nine patients were divided into three categories according to their response: 28 (40.6%) were unable to achieve a remission; 6 (8.7%) achieved a remission and subsequently had a relapse; and 35 (50.7%) were able to sustain a remission. The mean duration for sustained remissions was 33 months. Our earlier review of outcome of antithyroid therapy showed markedly reduced remission rates, which appeared to be related to increases in dietary iodine intake. Although the greater percentage of patients entering remission today is in marked contrast to the 1973 report, average dietary iodine content has been decreasing. A continuing role for antithyroid drugs should be maintained as an option in the management of Graves disease. Daily dietary iodine intake may influence the anticipated remission rate after antithyroid drug therapy.

Links

  • Publisher Full Text
  • Authors

    , , ,

    Source

    Annals of internal medicine 107:4 1987 Oct pg 510-2

    MeSH

    Adolescent
    Adult
    Aged
    Antithyroid Agents
    Diet
    Female
    Graves Disease
    Humans
    Iodine
    Male
    Middle Aged
    Organ Size
    Remission Induction
    Retrospective Studies
    Thyroid Gland

    Pub Type(s)

    Journal Article
    Research Support, U.S. Gov't, Non-P.H.S.

    Language

    eng

    PubMed ID

    2443050

    Citation

    Solomon, B L., et al. "Remission Rates With Antithyroid Drug Therapy: Continuing Influence of Iodine Intake?" Annals of Internal Medicine, vol. 107, no. 4, 1987, pp. 510-2.
    Solomon BL, Evaul JE, Burman KD, et al. Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med. 1987;107(4):510-2.
    Solomon, B. L., Evaul, J. E., Burman, K. D., & Wartofsky, L. (1987). Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Annals of Internal Medicine, 107(4), pp. 510-2.
    Solomon BL, et al. Remission Rates With Antithyroid Drug Therapy: Continuing Influence of Iodine Intake. Ann Intern Med. 1987;107(4):510-2. PubMed PMID: 2443050.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Remission rates with antithyroid drug therapy: continuing influence of iodine intake? AU - Solomon,B L, AU - Evaul,J E, AU - Burman,K D, AU - Wartofsky,L, PY - 1987/10/1/pubmed PY - 1987/10/1/medline PY - 1987/10/1/entrez SP - 510 EP - 2 JF - Annals of internal medicine JO - Ann. Intern. Med. VL - 107 IS - 4 N2 - We retrospectively reviewed the therapeutic efficacy of antithyroid drugs for Graves disease. Sixty-nine patients were divided into three categories according to their response: 28 (40.6%) were unable to achieve a remission; 6 (8.7%) achieved a remission and subsequently had a relapse; and 35 (50.7%) were able to sustain a remission. The mean duration for sustained remissions was 33 months. Our earlier review of outcome of antithyroid therapy showed markedly reduced remission rates, which appeared to be related to increases in dietary iodine intake. Although the greater percentage of patients entering remission today is in marked contrast to the 1973 report, average dietary iodine content has been decreasing. A continuing role for antithyroid drugs should be maintained as an option in the management of Graves disease. Daily dietary iodine intake may influence the anticipated remission rate after antithyroid drug therapy. SN - 0003-4819 UR - https://www.unboundmedicine.com/medline/citation/2443050/full_citation L2 - https://www.annals.org/article.aspx?volume=107&issue=4&page=510 DB - PRIME DP - Unbound Medicine ER -